Skip to main content

Triamcinolone ophthalmic Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Dec 20, 2022.

Triamcinolone ophthalmic is also known as: Triesence, Trivaris, Xipere

Triamcinolone ophthalmic Pregnancy Warnings

Animal studies have shown this drug to be teratogenic. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: D

-Studies suggest that maternal corticosteroid use during the first trimester increases the rate of cleft lip with or without cleft palate.
-Studies have shown decreased birth weight in infants exposed to maternal corticosteroids in utero.
-Infants born to mothers who received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.

See references

Triamcinolone ophthalmic Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Yes

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Triesence (triamcinolone ophthalmic)." Alcon Laboratories Inc (2007):

References for breastfeeding information

  1. "Product Information. Triesence (triamcinolone ophthalmic)." Alcon Laboratories Inc (2007):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.